Taha Qazi1,2, Thelina Amaratunga3, Edward L Barnes2,4, Monika Fischer5, Zain Kassam6, Jessica R Allegretti1,2. 1. a Division of Gastroenterology , Brigham and Women's Hospital , Brookline , MA , USA. 2. b Harvard Medical School , Boston , MA , USA. 3. c Department of Radiology , University of Manitoba , Winnipeg , MB , Canada. 4. f Division of Gastroenterology and Hepatology , University of North Carolina at Chapel Hill , Chapel Hill , NC , USA. 5. d Department of Gastroenterology , Indiana University School of Medicine , Indianapolis , IN , USA. 6. e OpenBiome , Somerville , MA , USA.
Abstract
Several studies have suggested worsening in inflammatory bowel disease (IBD) activity following fecal microbiota transplantation (FMT). We aimed to assess the risk of worsening in IBD activity following FMT. An electronic search was conducted using MEDLINE (1946-June 2016), EMBASE (1954-June 2016) and Cochrane Central Register of Controlled Trials (2016). Studies in which FMT was provided to IBD patients for IBD management or (Clostridium difficile infection) CDI treatment were included. The primary outcome was the rate of worsening in IBD activity. RESULTS: Twenty-nine studies with 514 FMT-treated IBD patients were included. Range of follow up was 4 weeks to 3 y. The pooled rate of IBD worsening was 14.9% (95% CI 10-21%). Heterogeneity was detected: I2 D 52.1%, Cochran Q test D 58.1, p D 0.01. A priori subgroup analyses were performed. Although not significant, the pooled rate of worsening in IBD activity following FMT for CDI (22.7% (95% CI: 13-36%)) was higher compared with FMT for IBD (11.1% (95% CI 7-17%)). Rates of worsening in IBD after lower GI FMT delivery revealed a higher rate of worsening in IBD activity (16.5% (95% CI: 11-24%)) compared with upper GI delivery (5.6% (95% CI: 2-16%)). Rates of worsening in high quality studies and randomized controls trials (RCTS) suggested a marginal risk of worsening in IBD activity (4.6%, (95% CI: 1.8-11%). Rates of IBD worsening are overall marginal across high quality RCTS. It is unknown if the FMT itself led to the worsening of IBD in this small fraction or if this represents alternative etiologies.
Several studies have suggested worsening in inflammatory bowel disease (IBD) activity following fecal microbiota transplantation (FMT). We aimed to assess the risk of worsening in IBD activity following FMT. An electronic search was conducted using MEDLINE (1946-June 2016), EMBASE (1954-June 2016) and Cochrane Central Register of Controlled Trials (2016). Studies in which FMT was provided to IBD patients for IBD management or (Clostridium difficile infection) CDI treatment were included. The primary outcome was the rate of worsening in IBD activity. RESULTS: Twenty-nine studies with 514 FMT-treated IBD patients were included. Range of follow up was 4 weeks to 3 y. The pooled rate of IBD worsening was 14.9% (95% CI 10-21%). Heterogeneity was detected: I2 D 52.1%, Cochran Q test D 58.1, p D 0.01. A priori subgroup analyses were performed. Although not significant, the pooled rate of worsening in IBD activity following FMT for CDI (22.7% (95% CI: 13-36%)) was higher compared with FMT for IBD (11.1% (95% CI 7-17%)). Rates of worsening in IBD after lower GI FMT delivery revealed a higher rate of worsening in IBD activity (16.5% (95% CI: 11-24%)) compared with upper GI delivery (5.6% (95% CI: 2-16%)). Rates of worsening in high quality studies and randomized controls trials (RCTS) suggested a marginal risk of worsening in IBD activity (4.6%, (95% CI: 1.8-11%). Rates of IBD worsening are overall marginal across high quality RCTS. It is unknown if the FMT itself led to the worsening of IBD in this small fraction or if this represents alternative etiologies.
Authors: Manasi Agrawal; Olga C Aroniadis; Lawrence J Brandt; Colleen Kelly; Sarah Freeman; Christina Surawicz; Elizabeth Broussard; Neil Stollman; Andrea Giovanelli; Becky Smith; Eugene Yen; Apurva Trivedi; Levi Hubble; Dina Kao; Thomas Borody; Sarah Finlayson; Arnab Ray; Robert Smith Journal: J Clin Gastroenterol Date: 2016 May-Jun Impact factor: 3.062
Authors: Robert P Hirten; Ari Grinspan; Shih-Chen Fu; Yuying Luo; Mayte Suarez-Farinas; John Rowland; Eduardo J Contijoch; Ilaria Mogno; Nancy Yang; Tramy Luong; Philippe R Labrias; Inga Peter; Judy H Cho; Bruce E Sands; Jean Frederic Colombel; Jeremiah J Faith; Jose C Clemente Journal: Inflamm Bowel Dis Date: 2019-05-04 Impact factor: 5.325
Authors: Maribeth R Nicholson; Paul D Mitchell; Erin Alexander; Sonia Ballal; Mark Bartlett; Penny Becker; Zev Davidovics; Michael Docktor; Michael Dole; Grace Felix; Jonathan Gisser; Suchitra K Hourigan; M Kyle Jensen; Jess L Kaplan; Judith Kelsen; Melissa Kennedy; Sahil Khanna; Elizabeth Knackstedt; McKenzie Leier; Jeffery Lewis; Ashley Lodarek; Sonia Michail; Maria Oliva-Hemker; Tiffany Patton; Karen Queliza; George H Russell; Namita Singh; Aliza Solomon; David L Suskind; Steven Werlin; Richard Kellermayer; Stacy A Kahn Journal: Clin Gastroenterol Hepatol Date: 2019-04-19 Impact factor: 11.382
Authors: Jessica R Allegretti; Colleen R Kelly; Ari Grinspan; Benjamin H Mullish; Jonathan Hurtado; Madeline Carrellas; Jenna Marcus; Julian R Marchesi; Julie A K McDonald; Ylaine Gerardin; Michael Silverstein; Alexandros Pechlivanis; Grace F Barker; Jesus Miguens Blanco; James L Alexander; Kate I Gallagher; Will Pettee; Emmalee Phelps; Sara Nemes; Sashidhar V Sagi; Matthew Bohm; Zain Kassam; Monika Fischer Journal: Inflamm Bowel Dis Date: 2021-08-19 Impact factor: 5.325